Priyatosh Nath
Cancer researcher in Cherie-Ann Nathan's head and neck cancer group at LSU Health Shreveport, first author of a 2026 study showing that the mTOR inhibitor everolimus can turn immune-cold tumours hot in mice
Department of Otolaryngology-Head and Neck Surgery, LSU Health Shreveport (2024–2026, Nathan lab)
Head and neck squamous cell carcinoma with a mutated TP53 gene often resists immunotherapy because the tumours are immune-cold: few killer T cells get inside. Priyatosh Nath's 2026 study, with Cherie-Ann Nathan as senior author, tested whether blocking mTOR could change that. A preprint version appeared on bioRxiv in June 2026 and the paper was then published in Neoplasia.
In mouse tumours of this type, including lines resistant to anti-PD-1 therapy, everolimus, an approved mTOR inhibitor, slowed tumour growth and remodelled the tumour surroundings. More CD8 T cells and dendritic cells came in, regulatory T cells that dampen immunity went down, and the HIF-1alpha/VEGFA signal that recruits immune-suppressing myeloid cells and builds blood vessels was reduced. Everolimus also raised the chemokine signals TNF-alpha and CXCL10 and lowered PD-1 and PD-L1, which helped T cells kill again. These are mouse results; the authors propose testing everolimus with immunotherapy in patients likely to fail immunotherapy alone.
PubMed lists Nath at the Department of Otolaryngology-Head and Neck Surgery, LSU Health Shreveport, on papers since 2024, including a 2024 review on the growth-factor receptor FGFR2 in cutaneous squamous cell cancer with the same group and a 2025 review on the pharmacology of natural chalcones. The exact title could not be confirmed from an official page.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment NAT2026 First author: showed in syngeneic TP53-mutant head and neck cancer models that everolimus brings in CD8 T cells, reduces suppressive cells and PD-1/PD-L1, and slows tumour growth. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Priyatosh Nath.
ShowHide
- Cherie-Ann O. Nathan Head and neck surgeon and cancer researcher who tests whether drugs such as the mTOR inhibitor everolimus can help patients whose tumours resist immunotherapy.
- J. Silvio Gutkind Showed that persistent mTOR activation exhausts epidermal stem cells and accelerates skin ageing, and targets PI3K–mTOR signalling in head-and-neck cancer, including to make tumours respond to immunotherapy
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.